Core Viewpoint - The stock of Jinxin Fertility (01951) has risen over 3%, currently trading at 2.6 HKD, with a transaction volume of 45.4 million HKD, following the announcement of supportive policies for fertility and long-term care insurance in China [1] Group 1: Industry Developments - The National Medical Security Work Conference held on December 13 in Beijing emphasized adapting to population development strategies and promoting the development of maternity insurance and long-term care insurance [1] - The conference aims to reasonably enhance the medical expense coverage for prenatal examinations, striving for nationwide "no out-of-pocket" expenses for childbirth within the policy scope [1] - By 2025, all 31 provinces (regions, municipalities) and the Xinjiang Production and Construction Corps are expected to include eligible assisted reproductive projects in medical insurance, with 7 provinces achieving full coverage of hospitalization expenses for childbirth within the policy scope [1] - 95% of the coordinated areas will directly distribute maternity allowances to insured individuals [1] Group 2: Company Actions - Jinxin Fertility announced a decision by its board to utilize buyback authorization to repurchase shares in the open market for a total price of no less than 100 million HKD [1] - Last week, the company repurchased 23.2 million shares at a cost of 57.7 million HKD [1] - As of now, the company has completed the repurchase of 30.9 million shares this month, totaling 77.5 million HKD, and it plans to continue focusing on improving operational performance and enhancing intrinsic value for sustainable shareholder returns [1]
锦欣生殖涨超3% 生育支持迎来利好 公司上周回购逾2322万股